ENDURE: ONS Symposium May 5th 2017

May 5, 2017

The goal of this educational activity to improve healthcare providers’ knowledge of a new novel treatment strategy for patients with breast cancer.  

Learning Objectives

After completing this activity, the participant should be better able to:

  • Review current research on the use of CDK 4/6 inhibitors for breast cancer patients, including  pre-clinical data, biomarker targets and sensitivity and resistance mechanisms
  • Discuss the MOA of CDK 4/6 inhibitors
  • Review clinical trial data on CDK 4/6 inhibitors, including efficacy and safety data
  • Identify appropriate patient selection for the use of CDK 4/6 inhibitors
  • Review the toxicity profiles of CDK 4/6 inhibitors
  • Apply strategies to manage neutropenia and other adverse events
  • Discuss existing and emerging clinical trial data associated with adverse events of combination  therapies using CDK 4/6 inhibitors
  • Discuss ways to enhance clinician/patient communication to improve patient outcomes
  • Apply shared decision-making strategies in the management of patients with breast cancer
Course summary
Available credit: 
  • 1.50 ACPE - Pharmacist
  • 1.50 ANCC
  • 1.50 JA Credit - AH
Registration Opens: 
Registration Expires: 
Activity Starts: 
05/05/2017 - 11:45am EDT
Activity Ends: 
05/05/2017 - 1:45pm EDT
Hyatt Regency Denver Convention Center
Centennial F-G 650
650 15th Street
Denver , CO
United States

P.Kelly Marcom, MD

Linda Sutton, MD

Kerri Dalton, MSN, RN, AOCNS

Melanie Watson, MSN, RN

Richard Finn, MD

Donna Topping PharmD


Available Credit

  • 1.50 ACPE - Pharmacist
  • 1.50 ANCC
  • 1.50 JA Credit - AH
Please login or register to take this course.